Orion: Annual Summary of Stock Exchange Releases and Announcements published in 2007

In accordance with Chapter 2, Section 10 c of the Finnish Securities Market Act, Orion Corporation publishes an Annual Summary of the stock exchange releases and announcements published by the company in 2007. The releases and announcements are available on the internet website of Orion Corporation, at www.orion.fi/investors. Orion points out that part of the information in the releases can have become out-dated.

 

24.01.2007	Change in the Executive Management Board of the Orion Group as of 1 February 2007
24.01.2007	Share-based incentive plan for ca. 30 key persons in Orion
29.01.2007	Recommendation by the Nomination Committee concerning Board of Directors to be elected by the AGM of Orion Corporation
06.02.2007	Bulletin of Orion Corporation Financial Statements for 1 July - 31 December 2006
06.02.2007	Orion Group Financial Review (proforma) 1-12/2006
06.02.2007	Orion updates progress with Simdax (i.v. levosimendan):
06.02.2007	Matters to be handled at Orion's AGM on 2 April 2007
01.03.2007	Orion Group Annual Report 2006 published
08.03.2007	Amendment to the Annual Report 2006 of Orion Corporation concerning holdings of Board members
02.04.2007	Decisions by the AGM of Orion Corporation on 2 April 2007
02.04.2007	Jukka Ylppö Vice Chairman of the Board of Directors of Orion Corporation. Compositions of Board committees
25.04.2007	Orion's partner discontinues development of levosimendan (Simdax) in the US
25.04.2007	Orion Group Interim Report 1-3/2007
06.08.2007	Orion Group Interim Report 1-6/2007
06.08.2007	Decision of the Board of Directors of Orion on repurchasing own shares
13.08.2007	Orion comments on ANDA filing of generic entacapone (Orion's proprietary drug Comtan®) in the United States
11.09.2007	New President and CEO for Orion Corporation as of 1 January 2008
13.09.2007	Orion sues generic drug companies in the U.S. to enforce patents for entacapone (Orion's proprietary drug Comtan®)
01.10.2007	Orion comments on ANDA filing of generic versions of Orion's proprietary drug Stalevo® in the United States
24.10.2007	Orion Group Interim Report 1-9/2007
24.10.2007	Orion Corporation's publication schedules for financial reporting in 2008
24.10.2007	Composition of the Nomination Committee of Orion Corporation
13.11.2007	Orion sues Sun Pharmaceuticals in the U.S. to enforce a patent for Stalevo®
15.11.2007	Appointments into Orion's Executive Management Board as of 1 January 2008
27.11.2007	Announcement by Orion Corporation in accordance with section 10 of chapter 2 of the Finnish Securities Market Act

 

18.01.2007	223,000 Orion A-shares converted into B-shares
26.01.2007	70,000 Orion A-shares converted into B-shares
19.04.2007	Changes in Orion's Articles of Association entered in the Trade Register on 19 April 2007
26.04.2007	905,839 Orion A-shares converted into B-shares
21.05.2007	532,051 Orion A-shares converted into B-shares
21.06.2007	335,315 Orion A-shares converted into B-shares
06.07.2007	100,000 Orion A-shares converted into B-shares
31.08.2007	398,000 Orion A-shares converted into B-shares
07.11.2007	171,347 Orion A-shares converted into B-shares
17.12.2007	260,000 Orion A-shares converted into B-shares

 

 

 

Orion Corporation

 

 

 

Timo Lappalainen           Olli Huotari

President and CEO        Senior VP, Corporate Functions

 

 

 

Orion is dedicated to treating and preventing disease by discovery and developing innovative medicinal treatments. In 2007, Orion generated net sales of EUR 683.6 million, invested EUR 97.6 million in research and development and employed approximately 3,160 people. Orion corporate headquarters are in Espoo, Finland.  For more information, please visit: http://www.orion.fi/english/.

 

 

 

 

 

Publisher:

Communications

Orionintie 1A, FI-02200 Espoo

Homepage: www.orion.fi